MedTrace Logo

Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country

NCT02806544 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-01-30

Study results available
· View outcomes & findings →

Summary

This study evaluates the feasibility and efficacy of neoadjuvant tamoxifen for patients with locally advanced hormone receptor positive breast cancer in a low/middle income country.

Conditions

Interventions

DRUG

Tamoxifen

Tamoxifen 20mg by mouth daily

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Instituto National de Cancerologia, Guatemala

    collaborator UNKNOWN

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Laila Agrawal, MD · Vanderbilt University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-09-30
Completion
2014-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806544 on ClinicalTrials.gov